Food and Drug Administration (FDA) announced on January 28th, 2025, that Ozempic (semaglutide, Novo Nordisk) is now approved to reduce the risk of kidney disease worsening, kidney failure, and death from cardiovascular disease in adults with type 2 diabetes and chronic kidney disease (CKD)
Battelino T, Lalic N, Hussain S, et al
In the United States, AbbVie used a combination of patent thickets and litigation settlements to prevent biosimilar entry until 2023
These site specific methodologies are listed in Table IV
The primary endpoint was all-cause mortality, and secondary endpoints were AMI, ischemic stroke, hemorrhagic stroke, atrial fibrillation (A-Fib)/flutter, cardiac arrest, readmission rate, and achievement of HbA1c (blood sugar) levels below 7%
So when you see a product called L-Carnitine 3000 make sure to check the supplement facts